doi: 10.1161/hc5001.100793
(Circulation. 2001;104:3063.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction
A Systematic Review
From the Department of Cardiology (S.M.B., N.R.B., A.H.M.M., R.J.G.P.), Department of Internal Medicine (M.L.), and Department of Vascular Medicine (H.R.B.), Academic Medical Center, Amsterdam, Netherlands.
Correspondence to R.J.G. Peters, Department of Cardiology, Room F3-236, Academic Medical Center, Meibergdreef 9, 1105AZ, PO Box 22660, 1100 DD, Amsterdam, Netherlands. E-mail r.j.peters{at}amc.uva.nl
Background— It is pathophysiologically conceivable that genetic variations in coagulation and fibrinolytic proteins are associated with the risk of myocardial infarction.
Methods and Results— We performed a literature search to identify published case-control studies correlating the factor V Leiden or prothrombin G20210A mutations or fibrinogen G-455A or plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphisms with the risk of myocardial infarction. Studies were included only if they used solid diagnostic criteria and complied with published methodological criteria. A common OR with corresponding 95% CI was calculated for the risk of myocardial infarction in a fixed-effect model according to Mantel-Haenszel. The factor V Leiden and prothrombin G20201A mutations did not significantly correlate with myocardial infarction (OR 1.26, 95% CI 0.94 to 1.67, P=0.12 and OR 0.89, 95% CI 0.59 to 1.35, P=0.6, respectively). Inclusion of the studies that investigated young patients (<55 years) made the association significant for factor V Leiden (OR 1.29, 95% CI 1.03 to 1.61, P=0.02). Homozygosity for the fibrinogen -455A allele was significantly associated with a decreased risk of myocardial infarction (OR 0.66, 95% CI 0.44 to 0.99, P=0.04), whereas the PAI-1 4G4G genotype was significantly associated with increased risk (OR 1.20, 95% CI 1.04 to 1.39, P=0.04).
Conclusions— Associations between these genetic variations and myocardial infarction were weak or absent. In the absence of clinical implications, our results indicate that screening of patients with myocardial infarction for these genetic variations is not warranted.
Key Words: myocardial infarction • genetics • coagulation
This article has been cited by other articles:
 |
|
 |
|
  J. P. A. Ioannidis Effect of Formal Statistical Significance on the Credibility of Observational Associations Am. J. Epidemiol., July 8, 2008; (2008) kwn156v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Arnett and for the Writing Group Summary of the American Heart Association's Scientific Statement on the Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1682 - 1686. [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Sternlicht, A. M. Dunning, D. H. Moore, P. D.P. Pharoah, D. G. Ginzinger, K. Chin, J. W. Gray, F. M. Waldman, B. A.J. Ponder, and Z. Werb Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 Expression. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Coppens, M. H. van de Poel, I. Bank, K. Hamulyak, J. van der Meer, N. J. Veeger, M. H. Prins, H. R. Buller, and S. Middeldorp A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation Blood, October 15, 2006; 108(8): 2604 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Keavney, J. Danesh, S. Parish, A. Palmer, S. Clark, L. Youngman, M. Delepine, M. Lathrop, R. Peto, R. Collins, et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization' Int. J. Epidemiol., August 1, 2006; 35(4): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
 |
|
 Prepared by: British Cardiac Society, British Hype JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice Heart, December 1, 2005; 91(suppl_5): v1 - v52. [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jood, P. Ladenvall, A. Tjarnlund-Wolf, C. Ladenvall, M. Andersson, S. Nilsson, C. Blomstrand, and C. Jern Fibrinolytic Gene Polymorphism and Ischemic Stroke Stroke, October 1, 2005; 36(10): 2077 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kathiresan, S. B. Gabriel, Q. Yang, A. L. Lochner, M. G. Larson, D. Levy, G. H. Tofler, J. N. Hirschhorn, and C. J. O'Donnell Comprehensive Survey of Common Genetic Variation at the Plasminogen Activator Inhibitor-1 Locus and Relations to Circulating Plasminogen Activator Inhibitor-1 Levels Circulation, September 20, 2005; 112(12): 1728 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andreotti and R. C. Becker Atherothrombotic Disorders: New Insights From Hematology Circulation, April 12, 2005; 111(14): 1855 - 1863. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bank, E. J. Libourel, S. Middeldorp, E. C. M. van Pampus, M. M. W. Koopman, K. Hamulyak, M. H. Prins, J. van der Meer, and H. R. Buller Prothrombin 20210A Mutation: A Mild Risk Factor for Venous Thromboembolism but Not for Arterial Thrombotic Disease and Pregnancy-Related Complications in a Family Study Arch Intern Med, September 27, 2004; 164(17): 1932 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pullmann Jr, M. Skerenova, J. Lukac, J. Hybenova, V. Melus, P. Kubisz, J. Rovensky, and R. Pullmann Factor V Leiden and Prothrombin G20210A Mutations and the Risk of Atherothrombotic Events in Systemic Lupus Erythematosus Clinical and Applied Thrombosis/Hemostasis, July 1, 2004; 10(3): 233 - 238. [Abstract] [PDF]
|
|
|
|
 |
|
 T. A. Sanders, T. de Grassi, J. Acharya, G. J Miller, and S. E Humphries Postprandial variations in fibrinolytic activity in middle-aged men are modulated by plasminogen activator inhibitor I 4G-675/5G genotype but not by the fat content of a meal Am. J. Clinical Nutrition, April 1, 2004; 79(4): 577 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Voetsch and J. Loscalzo Genetic Determinants of Arterial Thrombosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 216 - 229. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. H. Dwyer, H. Allayee, K. M. Dwyer, J. Fan, H. Wu, R. Mar, A. J. Lusis, and M. Mehrabian Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis N. Engl. J. Med., January 1, 2004; 350(1): 29 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Burzotta, K Paciaroni, V De Stefano, F Crea, A Maseri, G Leone, and F Andreotti G20210A Prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects Heart, January 1, 2004; 90(1): 82 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit Thrombophilia and New Anticoagulant Drugs Hematology, January 1, 2004; 2004(1): 424 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoekstra, J. M. Geleijnse, C. Kluft, E. J. Giltay, F. J. Kok, and E. G. Schouten 4G/4G Genotype of PAI-1 Gene Is Associated With Reduced Risk of Stroke in Elderly Stroke, December 1, 2003; 34(12): 2822 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Buyru, J. Altinisik, C. B. Gurel, and T. Ulutin PCR-RFLP Detection of PAI-2 Variants in Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, October 1, 2003; 9(4): 333 - 336. [Abstract] [PDF]
|
|
|
|
|
|
A. Festa, R. D'Agostino Jr, S. S. Rich, N. S. Jenny, R. P. Tracy, and S. M. Haffner Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study Circulation, May 20, 2003; 107(19): 2422 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.C Tanis Oral contraceptives and the risk of myocardial infarction Eur. Heart J., March 1, 2003; 24(5): 377 - 380. [Full Text] [PDF]
|
|
|
|
|
|
J. G. van der Bom, M. L. Bots, F. Haverkate, C. Kluft, and D. E. Grobbee The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1 Blood, March 1, 2003; 101(5): 1841 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J.G. Peters and S. M. Boekholdt Gene Polymorphisms and the Risk of Myocardial Infarction -- An Emerging Relation N. Engl. J. Med., December 12, 2002; 347(24): 1963 - 1965. [Full Text] [PDF]
|
|